Skip to main content
SpringerLink
Log in

A Meta-analysis of the Protective Effect of Recombinant Human Erythropoietin (rhEPO) for Neurodevelopment in Preterm Infants

  • Original Paper
  • Published:
Cell Biochemistry and Biophysics Aims and scope Submit manuscript

Abstract

The purpose of this study is to assess the efficacy and safety of recombinant human erythropoietin (rhEPO) for improving neurodevelopment outcomes in preterm infants. According to the requirements of Cochrane systematic review, a literature search was performed among PubMed, EMBASE, Cochrane Central Register of Controlled Trials, Chinese Biomedical Literature Database, Chinese National Knowledge Infrastructure, Wan Fang Data, and VIP INFORMATION from the establishment of the database from January 1999 to December 2011. Quality assessments of clinical trials were carried out. Randomized controlled trials (RCTs) or quasi-RCTs with rhEPO in preterm infants were enrolled, and RevMan5.0 software was used for meta-analysis. Data extraction, quality assessment, and meta-analysis for the results of homogeneous studies were done by two reviewers. The trials were analyzed using weighted mean difference (WMD) for continuous data and odds ratio (OR) for dichotomous data, both kinds of data were expressed by 95 % CI. For homogenous data (P ≥ 0.10), fixed effect model was calculated. Two RCTs and 3 quasi-RCTs including 233 preterm infants (119 of treatment group and 114 of control group) were included in the analysis. The results of quality assessment were that 1 study was A, 1 was B, and 3 were C. There was evidence of a significant effect of therapeutic rhEPO on the outcomes of MDI scores [WMD = 7.77, 95 % CI (3.49–12.06), P = 0.0004], PDI scores [WMD = 3.85, 95 % CI (0.62–7.09), P = 0.02] at 18–22 months and NBNA scores [WMD = 1.96, 95 % CI (1.56–2.37), P < 0.00001] at 40 weeks of corrected gestational age. However, rhEPO had no effect on MDI <70 (OR = 0.70, 95 % CI 0.31–1.61), PDI <70 (OR = 2. 46, 95 % CI 0.94–6.45), cerebral palsy (OR = 1.08, 95 % CI 0.39–2.99), blindness (OR = 0.34, 95 % CI 0.01–8.56), and hearing loss (OR = 1.04, 95 % CI 0.06–17.15). There were no differences between groups with respect to the percentage of preterm infants with severe retinopathy of prematurity of stage III or above (OR = 1.30, 95 % CI 0.50–3.43), severe intraventricular hemorrhage of stage III or above (OR = 2. 91, 95 % CI 0.64–13.23), necrotizing enterocolitis (OR = 0.57, 95 % CI 0.13–2.54), and borderline personality disorder (OR = 1. 06, 95 % CI 0.50–2.26). The rhEPO treatment has beneficial effect on the neurodevelopment outcomes without severe adverse side effect in preterm infants.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Gonzalez, F. F., & Ferriero, D. M. (2009). Neuroprotection in the newborn infant. Clinics in Perinatology, 36, 859–880.

    Article  PubMed Central  PubMed  Google Scholar 

  2. Volpe, J. J. (2003). Cerebral white matter injury of the premature infant-more common than you think. Pediatrics, 112, 176–180.

    Article  PubMed  Google Scholar 

  3. Felderhoff-Mueser, U., Bittigau, P., Sifringer, M., Jarosz, B., Korobowicz, E., Mahler, L., et al. (2004). Oxygen causes cell death in the developing brain. Neurobiology of Diseases, 17, 273–282.

    Article  CAS  Google Scholar 

  4. McPherson, R. J., & Juul, S. E. (2008). Recent trends in erythropoietin-mediated neuroprotection. International Journal of Developmental Neuroscience, 26, 103–111.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  5. Ghezzi, P., Bernaudinb, M., Bianchic, R., Blomgren, K., Brines, M., Campana, W., et al. (2010). Erythropoietin: Not just about erythropoiesis. Lancet, 375, 2142.

    Article  PubMed  Google Scholar 

  6. Gonzalez, F. F., & Ferriero, D. M. (2008). Therapeutics for neonatal brain injury. Pharmacology and Therapeutics, 120, 43–53.

    Article  CAS  PubMed  Google Scholar 

  7. McPherson, R. J. (2009). Can erythropoietin improve developmental outcomes for preterm infants? Pediatrics, 124, e805–e806.

    Article  PubMed  Google Scholar 

  8. Newton, N. R., Leonard, C. H., Piecuch, R. E., & Phibbs, R. H. (1999). Neurodevelopmental outcome of prematurely born children treated with recombinant human erythropoietin in infancy. Journal of Perinatology, 19, 403–406.

    Article  CAS  PubMed  Google Scholar 

  9. Ohls, R. K., Ehrenkranz, R. A., Das, A., Dusick, A. M., Yolton, K., Romano, E., et al. (2004). Neurodevelopmental outcome and growth at 18 to 22 months’ corrected age in extremely low birth weight infants treated with early erythropoietin and iron. Pediatrics, 114, 1287–1291.

    Article  PubMed  Google Scholar 

  10. Juul, S. E., McPherson, R. J., Bauer, L. A., Ledbetter, K. J., Gleason, C. A., & Mayock, D. E. (2008). A phase I/II trial of high-dose erythropoietin in extremely low birth weight infants: Pharmacokinetics and safety. Pediatrics, 122, 383–391.

    Article  PubMed  Google Scholar 

  11. Fauchere, J. C., Dame, C., Vonthein, R., Koller, B., Arri, S., Wolf, M., et al. (2008). An approach to using recombinant erythropoietin for neuroprotection in very preterm infants. Pediatrics, 122, 375–382.

    Article  PubMed  Google Scholar 

  12. Juni, P., Altman, D. G., & Egger, M. (2001). Systematic reviews in health care: Assessing the quality of controlled clinical trials. British Medical Journal, 323, 42–46.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  13. Jadad, A. R., Moore, R. A., Carroll, D., Jenkinson, C., Reynolds, D. J., Gavaghan, D. J., et al. (1996). Assessing the quality of reports of randomized clinical trials: Is blinding necessary? Controlled Clinical Trials, 17, 1–12.

    Article  CAS  PubMed  Google Scholar 

  14. Bierer, R., Peceny, M. C., Hartenberger, C. H., & Ohls, R. K. (2006). Erythropoietin concentrations and neurodevelopmental outcome in preterm infants. Pediatrics, 118(3), 635–640.

    Article  Google Scholar 

  15. Wang, Y. H. (2005). Effects of erythropoietin on anemia and nervous system of premature infants. Journal of Medical Forum, 26(7), 49–52.

    Google Scholar 

  16. Wang, Y. H., Zhu, C. L., Cheng, X. Y., Hu, S. H., Feng, H. Q., & Wang, X. Y. (2006). Effects of recombinant human erythropoietin on neurobehavioral development in premature infants. Chinese Journal of Practical Pediatrics, 12(1), 59–60.

    Google Scholar 

  17. He, J. S., Huang, Z. L., Yang, H., Weng, K. Z., & Zhu, S. B. (2008). Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants. Chinese Journal of Contemporary Pediatrics, 10(5), 586–588.

    PubMed  Google Scholar 

  18. Neubauer, A. P., Voss, W., Wachtendorf, M., & Jungmann, T. (2010). Erythropoietin improves neurodevelopmental outcome of extremely preterm infants. Annals of Neurology, 67, 657–666.

    CAS  PubMed  Google Scholar 

  19. Higgins, J., Thompson, S., Deeks, J., & Altman, D. (2002). Statistical heterogeneity in systematic reviews of clinical trials: A critical appraisal of guidelines and practice. Journal of Health Services Research and Policy, 7(1), 51–61.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, The Second Affiliated Hospital, Medical School of Xi’an Jiaotong University, Shaanxi, China

    Huiping Wang, Lan Zhang & Yan Jin

Authors
  1. Huiping Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lan Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yan Jin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Huiping Wang.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, H., Zhang, L. & Jin, Y. A Meta-analysis of the Protective Effect of Recombinant Human Erythropoietin (rhEPO) for Neurodevelopment in Preterm Infants. Cell Biochem Biophys 71, 795–802 (2015). https://doi.org/10.1007/s12013-014-0265-1

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12013-014-0265-1

Keywords

Search

Navigation